REG - Tristel PLC - Publication of Poster by Mayo Clinic & US update

TristelAnnouncement

09/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI1832Ea&default-theme=true

RNS Number : 1832E  Tristel PLC  09 April 2025

TRISTEL plc

("Tristel" or the "Company")

 

Publication of Poster by Mayo Clinic

North America update

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
notes the publication of a poster by the Mayo Clinic at the AORN* Global
Surgical Conference & Expo in Boston, MA (USA) published this week,
entitled, "Implementing a new method of High-Level disinfection foam for
ultrasound probes."

 

The poster reported on the outcome of a new method of High-Level Disinfection
("HLD"), Tristel ULT™, used in a 90-day trial by 11 Mayo Clinic staff
members to reprocess 189 ultrasound probes, with no reported surgical site
infections during the trial.

 

The poster described the new method of HLD foam as an effective and efficient
method for HLD of ultrasound probes with minimal reprocessing turn-around time
as well as being safe, easy to use, and cost effective. The poster also
describes how the new HLD foam reduces reprocessing time minimising the number
of ultrasound probes needed as well as reducing the damage to ultrasound
probes compared to other methods.

 

The full poster can be viewed here:
https://investors.tristel.com/wp-content/uploads/2025/04/AORN-Poster-Mayo-Clinic.pdf
(https://urldefense.proofpoint.com/v2/url?u=https-3A__investors.tristel.com_wp-2Dcontent_uploads_2025_04_AORN-2DPoster-2DMayo-2DClinic.pdf&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=wnSDcV-q9UPMz5NaLi6mKPo9-7jzVSEGmBzE7MIv1J90MtKSdL18gthpxHoH4Ut5&m=YQ35QvVNYm1xm00XEEAmsNr4hz39I2U4HTMrajKIcuMpzvlBhLPKQap1ICindX1h&s=xBIE0jcKmAzaQvlhnxb9HsaoYrssSxw0FBbeJo7sLx4&e=)

 

This positive case-study of US adoption follows the news announced in February
2025
(https://www.londonstockexchange.com/news-article/TSTL/unaudited-interim-results/16910827)
that an updated standard compiled by the Association for the Advancement of
Medical Instrumentation (AAMI) and adopted by the American National Standards
Institute (ANSI) acknowledged chlorine dioxide foam as a novel modality for
high-level disinfection of medical devices.

 

This also adds to the growing number of US case studies that highlight Tristel
ULT™ as a novel HLD able to achieve faster, simpler endocavitary probe
processing for busy urology practices. In May 2024, US urologist, Dr Matthew
Allaway, published a white paper called "Simplifying High-Level Disinfection
for Urological Procedures: A Case Study"
https://www.parkerlabs.com/wp-content/uploads/2024/04/AllawayWhitePaper_8_LOCKED.pdf
(https://www.parkerlabs.com/wp-content/uploads/2024/04/AllawayWhitePaper_8_LOCKED.pdf)

 

North America update

Sales of Tristel ULT in North America continue to build momentum, with strong
sequential growth delivered quarter on quarter in line with internal
forecasts.

 

The solid growth reflects increasing adoption of the Company's technology,
supported by growing customer engagement and expanding usage within existing
accounts. At the end of the third quarter, so far this financial year the
Company estimates that Tristel ULT had been used for over 200,000 disinfection
procedures in North America.

 

Matt Sassone, Chief Executive Officer of Tristel, commented: "We are delighted
to see such positive feedback on the use of Tristel ULT in clinical practice
at the renowned Mayo Clinic. As a leading US hospital, the Mayo Clinic pride
themselves in excellence and are always seeking to adopt the best possible
practices in infection control. To have them present this poster to the
thousands of perioperative professionals who attend this conference is a great
support to our plans to wider drive adoption in the US.

 

"We're confident in our continued momentum across North America and we look
forward to US revenues becoming substantial in the years ahead. As Tristel ULT
is manufactured in the United States by our partner, Parker Labs, we're
confident that the newly announced tariffs will have no adverse impact on our
pricing or sales performance in North America."

 

Notes

*Association of periOperative Registered Nurses

 

 

 

For further information please contact:

 

 Tristel plc                                                                  Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                        www.investors.tristel.com (http://www.investors.tristel.com/)
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                                                              Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Alice Woodings    Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

 Cavendish Capital Markets Ltd                                                Tel: 020 7220 0500
 Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (ECM) / Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25% and the
business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASLPEFPSEFA